# A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

> **NCT05348876** · PHASE4 · RECRUITING · sponsor: **Bayer** · enrollment: 50 (estimated)

## Conditions studied

- Non-metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Darolutamide (Nubeqa, BAY1841788)

## Key facts

- **NCT ID:** NCT05348876
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-03
- **Primary completion:** 2027-04-29
- **Final completion:** 2027-04-29
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05348876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05348876, "A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT05348876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*